AR045268A1 - Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento - Google Patents

Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento

Info

Publication number
AR045268A1
AR045268A1 ARP040102941A ARP040102941A AR045268A1 AR 045268 A1 AR045268 A1 AR 045268A1 AR P040102941 A ARP040102941 A AR P040102941A AR P040102941 A ARP040102941 A AR P040102941A AR 045268 A1 AR045268 A1 AR 045268A1
Authority
AR
Argentina
Prior art keywords
erbb2
overexpression
procedure
inhibitor
treatment
Prior art date
Application number
ARP040102941A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR045268A1 publication Critical patent/AR045268A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procedimiento para tratar la sobreexpresión de erbB2 en un mamífero que necesite tratamiento, administrando al mamífero una cantidad terapéuticamente eficaz de un primer inhibidor del receptor de erbB2 tirosina quinasas receptoras y después, tras un intervalo de menos de 24 horas, administrar al mamífero de una a seis cantidades terapéuticamente eficaces del mismo inhibidor o de un inhibidor diferente del receptor de erbB2. Infusión diaria lenta del inhibidor de erbB2. La sobreexpresión del receptor de erbB2 puede dar como resultado un crecimiento celular anormal y conducir a un cáncer. Mediante los procedimientos del presente, se aumenta la eficacia y la seguridad de los inhibidores. Kits para facilitar el procedimiento de administración de la dosis del presente.
ARP040102941A 2003-08-18 2004-08-17 Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento AR045268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
AR045268A1 true AR045268A1 (es) 2005-10-19

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102941A AR045268A1 (es) 2003-08-18 2004-08-17 Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento

Country Status (18)

Country Link
US (1) US20050119288A1 (es)
EP (1) EP1658080A1 (es)
JP (1) JP2007502807A (es)
KR (2) KR20060037447A (es)
CN (1) CN1838959A (es)
AR (1) AR045268A1 (es)
AU (1) AU2004264726A1 (es)
BR (1) BRPI0413745A (es)
CA (1) CA2536140A1 (es)
CO (1) CO5670356A2 (es)
IL (1) IL173127A0 (es)
MX (1) MXPA06001989A (es)
NO (1) NO20061252L (es)
RU (1) RU2328287C2 (es)
SG (1) SG135193A1 (es)
TW (1) TW200522966A (es)
WO (1) WO2005016347A1 (es)
ZA (1) ZA200600517B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US8318752B2 (en) 2003-09-19 2012-11-27 Astrazeneca Ab 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
AU2006259261B2 (en) * 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
AU2006315512B2 (en) * 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
EP2004165A2 (en) * 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
AU2007319825B2 (en) 2006-11-14 2014-01-23 Ariad Pharmaceuticals, Inc. Oral formulations
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
AU2008236994A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
ES2583377T3 (es) 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
WO2013078440A2 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CN110564604B (zh) * 2014-01-31 2023-09-29 凸版印刷株式会社 液滴的形成方法、生物分子分析方法及生物分子分析试剂盒
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69522717T2 (de) * 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
WO2003049740A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
HRP20040530A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
EP1567506A4 (en) * 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
AU2003303045A1 (en) * 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
EP1658080A1 (en) 2006-05-24
WO2005016347A1 (en) 2005-02-24
KR20060037447A (ko) 2006-05-03
KR20080014144A (ko) 2008-02-13
NO20061252L (no) 2006-05-16
RU2328287C2 (ru) 2008-07-10
CN1838959A (zh) 2006-09-27
BRPI0413745A (pt) 2006-10-24
CA2536140A1 (en) 2005-02-24
AU2004264726A1 (en) 2005-02-24
TW200522966A (en) 2005-07-16
JP2007502807A (ja) 2007-02-15
SG135193A1 (en) 2007-09-28
IL173127A0 (en) 2006-06-11
MXPA06001989A (es) 2006-05-17
ZA200600517B (en) 2007-02-28
CO5670356A2 (es) 2006-08-31
US20050119288A1 (en) 2005-06-02
RU2006102125A (ru) 2007-09-27

Similar Documents

Publication Publication Date Title
AR045268A1 (es) Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento
WO2021243280A3 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
PH12022552739A1 (en) Fused tricyclic kras inhibitors
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
CR9984A (es) Método de inhibición de cinasa de tirosina cinasa 3 similar a fms
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
WO2018102687A3 (en) Combination therapy for treating cancer
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
RU2013125042A (ru) Способ предотвращения или лечения опухоли кожи
MX2024014317A (es) Tratamientos con nirogacestat
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
WO2021142448A3 (en) Tgf-beta inhibitors and use thereof
NO20051170L (no) Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
MX2022013843A (es) Inhibidores de il4i1 y metodos de uso.
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal